TIDMSENS
RNS Number : 8943L
Sensyne Health PLC
05 May 2020
Sensyne Health announces launch of new BPm-Health (TM) remote
monitoring system for the management of blood
pressure in pregnancy in response to COVID-19 pandemic
Highlights :
-- BPm-Health (TM) will enable pregnant women to self-monitor
their blood pressure during pregnancy
-- Will help healthcare professionals provide remote care for
mums-to-be in line with UK government guidelines on social
distancing and provision of care away from hospitals &
clinics
-- Company will work collaboratively with the NHS to broaden use of the product across the UK
Oxford, U.K. 05 May 2020: Sensyne Health plc (LSE: SENS)
("Sensyne" or the "Company" or the "Group"), the UK Clinical AI
technology company, today announces it has launched BPm-Health to
help pregnant women monitor blood pressure remotely in response to
the UK government guidelines for all pregnant women to follow
stringent social distancing and minimise face-to-face contact.
BPm-Health will be offered free to the NHS for one year to
support hospital maternity services during the coronavirus
pandemic. The formal launch of the product comes after the
successful completion of recruitment of a 3000 participant
multicentre trial (BuMP) involving 15 NHS Trusts, led by the
Nuffield Department of Primary Care Health Sciences, University of
Oxford. The BuMP app was transferred to Sensyne Health earlier this
year and re-engineered under the company's Quality Management
System.
BPm-Health is one of three apps listed by the Royal College of
Obstetricians and Gynecologists (RCOG) in its recent guidance
'Self-monitoring of blood pressure in pregnancy' ([1]) .
The announcement follows the high interest and uptake by the NHS
of Sensyne Health's offer, announced on 27 March 2020, to provide
GDm-Health, a remote monitoring system for the management of
diabetes in pregnancy, free to the NHS for one year.
There has been an increasing recognition of the acceptability
and benefits of self-monitoring of blood pressure during pregnancy
(see references below). The COVID-19 pandemic is now increasing the
need for healthcare professionals to advocate blood pressure
self-monitoring in order to reduce face-to-face consultations for
pregnant whilst maintaining care for the woman and her baby.
BPm-Health aims to help expectant mothers to self-monitor their
blood pressure, communicating results to their healthcare team
remotely rather than at face-to-face clinic appointments. Women are
sent alerts when it is time to take a reading, and can then record
data on the patient app. The app displays RCOG advice on what women
should do dependent on the results submitted.
Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:
"This is now the launch of a second Sensyne product in the field
of women's health and our fourth in the area of remote patient
monitoring. Sensyne is seeing increasing demand for its products
and technology as healthcare systems adapt to the current situation
and make plans to digitise quickly for a post-COVID-19 future."
Dr Lucy Mackillop , Chief Medical Officer of Sensyne Health plc
and consultant obstetric physician at Oxford University Hospitals
NHS Foundation Trust and Honorary Senior Clinical Lecturer,
Nuffield Department of Women's and Reproductive Health, University
of Oxford, said:
"As a practicing consultant obstetric physician, I'm acutely
aware that the pandemic is a cause of worry for expectant mothers
as access to antenatal and postnatal services has been modified and
some face-to-face appointments have been postponed.
I welcome today's launch of BPm-Health which will help NHS
maternity services to support women to observe UK government
guidelines on social distancing by remote monitoring of their blood
pressure, while maintaining the delivery of high-quality care.
This technology adds an additional tool for women's heath,
helping the NHS remotely manage pregnant women, maintain existing
planned clinic appointments and provide the right care both during
the COVID-19 pandemic, and long after it. BPm-Health is an
excellent accompaniment to the work we have already done with
GDm-Health, an award-winning app helping mothers-to-be manage
diabetes in pregnancy at home."
BPm-Health is a collaboration between University of Oxford's
Nuffield Department of Primary Care Health Sciences, Institute of
Biomedical Engineering and Sensyne Health led by Dr Lucy Mackillop,
a consultant Obstetric Physician at Oxford University Hospitals NHS
Foundation Trust, Honorary Senior Clinical Lecturer in women's and
reproductive health at the University of Oxford, and Chief Medical
Officer at Sensyne Health.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Michael Norris, Interim Chief Financial
Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Oliver Jackson
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications +44 (0) 7780 600290
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in
partnership with the NHS to improve patient care and accelerate the
discovery and development of new medicines. Sensyne Health is
listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com
References
1. McManus RJ, Mant J,Franssen M, Nickless A, Schwartz C,
Hodgkinson J, et al. Efficacy of self-monitored blood pressure,
with or without telemonitoring, for titration of antihypertensive
medication (TASMINH4): an unmasked randomised controlled trial.
Lancet. 2018; 391(10124):949-59.
2. McManusRJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S,
et al. Telemonitoring and self-management in the control of
hypertension (TASMINH2): a randomised controlled trial. Lancet.
2010; 376(9736):163-72.
3. McManusRJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM,
et al. Effect of self-monitoring and medication self-titration on
systolic blood pressure in hypertensive patients at high risk of
cardiovascular disease: the TASMIN-SR randomized clinical trial.
JAMA. 2014;312(8):799-808.
4. PealingLM, Tucker KL, Mackillop LH, Crawford C, Wilson H,
Nickless A, et al. A randomised controlled trial of blood pressure
self-monitoring in the management of hypertensive pregnancy.
OPTIMUM-BP: A feasibility trial. Pregnancy Hypertens.
2019;18:141-9.
5. Cairns AE, Tucker KL, Leeson P, Mackillop LH, Santos M,
Velardo C, et al. Self-Management of Postnatal Hypertension: The
SNAP-HT Trial. Hypertension.2018.
6. TuckerKL, Taylor KS, Crawford C, Hodgkinson JA, Bankhead C, Carver T, et al. Blood pressure self-monitoring in pregnancy: examining feasibility in a prospective cohort study. BMC Pregnancy Childbirth. 2017;17(1):442.
7. HintonL, Tucker KL, Greenfield SM, Hodgkinson JA, Mackillop
L, McCourt C, et al.Blood pressure self-monitoring in pregnancy
(BuMP) feasibility study; a qualitative analysis of women's
experiences of self-monitoring. BMC PregnancyChildbirth.
2017;17(1):427.
8. GrantS, Hodgkinson J, Schwartz C, Bradburn P, Franssen M,
Hobbs FR, et al. Using mHealth for the management of hypertension
in UK primary care: an embedded qualitative study of the TASMINH4
randomised controlled trial. Br J Gen Pract.
2019;69(686):e612-e20.
9. JonesMI, Greenfield SM, Bray EP, Baral-Grant S, Hobbs FD,
Holder R, et al. Patients' experiences of self-monitoring blood
pressure and self-titration of medication: the TASMINH2 trial
qualitative study. Br J Gen Pract. 2012;62(595):e135-e42.
10. Tucker KL, Bowen L, Crawford C, Mallon P,Hinton L, Lee MM,
et al. The feasibility and acceptability of self-testing for
proteinuria during pregnancy: A mixed methods approach. Pregnancy
Hypertens. 2018;12:161-8.
[1] Royal College of Obstetricians and Gynecologists.
'Self-monitoring of blood pressure in pregnancy' Information for
healthcare professionals. Version 1 30 March 2020
https://www.rcog.org.uk/globalassets/documents/guidelines/2020-03-30-self-monitoring-of-blood-pressure-in-pregnancy.pdf
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCAIMTTMTMMTJM
(END) Dow Jones Newswires
May 05, 2020 05:21 ET (09:21 GMT)
Grafico Azioni Sensyne Health (LSE:SENS)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Sensyne Health (LSE:SENS)
Storico
Da Apr 2023 a Apr 2024
